EVERY MAN IS DIFFERENT, EVERY PROSTATE CANCER IS UNIQUE.
Are you making the most informed treatment decision?

KNOW THE FACTS BEFORE YOU BEGIN TREATMENT

OVER 50% OF NEWLY-DIAGNOSED MEN HAVE LOW-RISK PROSTATE CANCER THAT IS UNLIKELY TO SPREAD.

YET A MAJORITY OF THEM RECEIVE IMMEDIATE AGGRESSIVE TREATMENT which may lead to impotence and incontinence.

MISCONCEPTIONS WOMEN AND MEN HAVE ABOUT PROSTATE CANCER

<table>
<thead>
<tr>
<th>HIGH RISK</th>
<th>LIFE THREATENING</th>
<th>BEST TREATED IMMEDIATELY</th>
</tr>
</thead>
<tbody>
<tr>
<td>47%</td>
<td>51%</td>
<td>59%</td>
</tr>
<tr>
<td>53%</td>
<td>49%</td>
<td>42%</td>
</tr>
</tbody>
</table>

Not knowing which treatment to choose with confidence and potential side effects rank as men’s top concerns.

A LESS AGGRESSIVE APPROACH MIGHT BE THE BEST CHOICE FOR YOU

ACTIVE SURVEILLANCE

This is a program that regularly monitors cancer for progression that allows some patients to avoid immediate treatment and the accompanying side effects.

ASK YOUR DOCTOR ABOUT A GENOMIC TEST to help you make the right decision.

VISIT YourProstateYourDecision.com TO FIND OUT MORE.
ACTIVE SURVEILLANCE OR IMMEDIATE TREATMENT?

The Onco
type DX® Prostate Cancer Assay helps you and your doctor choose with confidence.

Identified for ACTIVE SURVEILLANCE

PSA 6.2
Gleason Score 6
Oncotype DX® GPS 11

The Oncotype DX Prostate Cancer Assay provides precise and more accurate information about your cancer, so you and your doctor can confidently choose an individualized treatment plan that’s right for you.

For more information, visit OncotypeDX.com/prostate